FY2025 · ended Dec 31, 2025 · Revenue $14.08M, +128.2% YoY · Filed Mar 23, 2026
Arbutus Biopharma Corp (ABUS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $14.1 million and a net loss of $33.5 million. Free cash flow was -$39.6 million. As of Jun 30, 2026 it held $92.6 million in cash and investments and $514,000 in total debt.
Revenue (TTM)
$181.72M
+1078.8% vs year-ago TTM
Net income (TTM)
$153.05M
+382.1% vs year-ago TTM
Operating cash flow (TTM)
$-24.62M
+59.1% vs year-ago TTM
Free cash flow
$-39.64M
+39.1% vs prior year
EPS (TTM)
$0.79
+376.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
195.48M
+2.1% vs prior year
Net cash
$92.11M
as of Jun 30, 2026
Operating margin
82.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABUS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Warminster, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1447028
- Former names
- TEKMIRA PHARMACEUTICALS CORP (until Aug 3, 2015); TEKMIRA PHARMACEUTICALS Corp (until Aug 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M |
| Operating income | -$38.2M | -$76.3M | -$78.1M | -$65.5M | -$73.5M |
| Net income | -$33.5M | -$69.9M | -$72.8M | -$69.5M | -$76.2M |
| Diluted EPS | -$0.17 | -$0.38 | -$0.44 | -$0.46 | -$0.83 |
| Operating cash flow | -$39.6M | -$64.8M | -$85.9M | -$35.4M | -$67.5M |
| Free cash flow | -$39.6M | -$65.0M | -$86.9M | -$35.9M | -$68.3M |
| Total assets | $94.6M | $131.7M | $144.4M | $195.4M | $204.5M |
| Total liabilities | $18.0M | $34.3M | $38.4M | $58.6M | $35.0M |
| Stockholders' equity | $76.6M | $97.4M | $106.0M | $136.9M | $169.4M |
| Cash and investments | $91.5M | $122.6M | $132.3M | $184.3M | $191.0M |
| Total debt | $746,000 | $1.3M | $1.8M | $2.2M | $2.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Other events
|
Aug 21, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Agreement ended, Officer or director change, Other events
|
Jul 16, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 27, 2026 | May 26, 2026 |
All 1000 Arbutus Biopharma Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.